GLAD-PCR assay of DNA methylation sites in regulatory regions of some tumor-suppressor genes in breast cancer

Author:

Smetannikova N. A.1ORCID,Abdurashitov M. A.2,Akishev A. G.2,Pozdnyakov P. I.1,Dubinin E. V.3ORCID,Karpov A. B.4ORCID,Vihlyanov I. V.5,Nikitin M. K.5,Soldatova S. M.6,Netesova N. A.1ORCID

Affiliation:

1. State Research center of Virology and Biotechnology «Vector»

2. Sibenzyme Ltd

3. Epigene Ltd

4. Seversk Biophysical Research Centre; Siberian State Medical University

5. Altai Regional Oncology Center

6. Siberian Federal Research And Clinical Centre

Abstract

Hypermethylation of the RcgY sites is shown for many cancer diseases. such aberrant methylation, suppressing the gene activity, occurs at early stages of carcinogenesis. Recently, using glad-pcR assay, we have detected aberrantly methylated RcgY sites, which can be considered to be epigenetic markers of colorectal, lung, and gastric cancers. in breast cancer, methylation of the regulatory regions of ALX4, BMP2, CCND2, CDH13, CDX1, FOXA1, GALR1, GATA5, GREM1, HIC1, HMX2, HS3ST2, HOXC10, ICAM5, LAMA1, RARB, RASSF1A, RUNX3, RXRG, RYR2, SFRP2, SOX17, TERT, and ZNF613 tumor-suppressor genes is reported. in the present work, we determined aberrantly methylated RcgY sites in the regulatory regions of these genes in dNa preparations from breast cancer tissues. the study of dNa samples from 30 tumor and 22 normal mammary tissue samples demonstrates a high diagnostic potential of selected R(5mc)gY sites in regulatory regions of CCND2, BMP2, GALR1, SOX17, HMX2, and HS3ST2 genes with total index of sensitivity and specificity for R(5mc)gY detection in tumor dNa 90.0 % and 100.0 %, respectively.

Publisher

Tomsk Cancer Research Institute

Subject

Cancer Research,Oncology

Reference36 articles.

1. GLOBOCAN 2020 Database Provides Latest Global Data on Cancer Burden, Cancer Deaths [Internet]. URL: https://ascopost.com/news/december-2020/globocan-2020-database-provides-latest-global-data-oncancer-burden-cancer-deaths/ (cited 19.04.2021).

2. Guide to cancer early diagnosis. Geneva: World Health Organization, 2018. 38 p. (in Russian).

3. Breast Cancer Survival Rates [Internet]. URL: https://www.webmd.com/breast-cancer/guide/breast-cancer-survival-rates (19.04.2021).

4. Hesson L.B., Pritchard A.L. Clinical Epigenetics. Springer Singapore, 2019. P. 153–171. doi: 10.1007/978-981-13-8958-0.

5. Gao L., Emperle M., Guo Y., Grimm S.A., Ren W., Adam S., Uryu H., Zhang Z.M., Chen D., Yin J., Dukatz M., Anteneh H., Jurkowska R.Z., Lu J., Wang Y., Bashtrykov P., Wade P.A., Wang G.G., Jeltsch A., Song J. Comprehensive structure-function characterization of DNMT3B and DNMT3A reveals distinctive de novo DNA methylation mechanisms. Nat Commun. 2020 Jul 3; 11(1): 3355. doi: 10.1038/s41467-020-17109-4.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3